These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
88 related articles for article (PubMed ID: 3131718)
1. The mechanism of inactivation of the normal c-myc gene locus in human Burkitt lymphoma cells. Nishikura K; Murray JM Oncogene; 1988 May; 2(5):493-8. PubMed ID: 3131718 [TBL] [Abstract][Full Text] [Related]
2. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift. Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472 [TBL] [Abstract][Full Text] [Related]
3. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt's lymphoma line. Bemark M; Neuberger MS Oncogene; 2000 Jul; 19(30):3404-10. PubMed ID: 10918597 [TBL] [Abstract][Full Text] [Related]
4. Expression of P0- and P3-RNA from the normal and translocated c-myc allele in Burkitt's lymphoma cells. Eick D; Polack A; Kofler E; Lenoir GM; Rickinson AB; Bornkamm GW Oncogene; 1990 Sep; 5(9):1397-402. PubMed ID: 2216463 [TBL] [Abstract][Full Text] [Related]
5. Translocated c-myc genes produce chimeric transcripts containing antisense sequences of the immunoglobulin heavy chain locus in mouse plasmacytomas. Julius MA; Street AJ; Fahrlander PD; Yang JQ; Eisenman RN; Marcu KB Oncogene; 1988 May; 2(5):469-76. PubMed ID: 2453828 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of the translocated c-myc in Burkitt's lymphoma by a PNA complementary to the E mu enhancer. Cutrona G; Carpaneto EM; Ponzanelli A; Ulivi M; Millo E; Scarfì S; Roncella S; Benatti U; Boffa LC; Ferrarini M Cancer Res; 2003 Oct; 63(19):6144-8. PubMed ID: 14559793 [TBL] [Abstract][Full Text] [Related]
7. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells. Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212 [TBL] [Abstract][Full Text] [Related]
8. Expression of the L-myc gene is under positive control by short-lived proteins. Saksela K Oncogene; 1987; 1(3):291-6. PubMed ID: 2838780 [TBL] [Abstract][Full Text] [Related]
9. Analysis of c-myc expression in a human hepatoma cell line. Huber BE; Thorgeirsson SS Cancer Res; 1987 Jul; 47(13):3414-20. PubMed ID: 3034414 [TBL] [Abstract][Full Text] [Related]
10. The role of immunoglobulin kappa elements in c-myc activation. Hörtnagel K; Mautner J; Strobl LJ; Wolf DA; Christoph B; Geltinger C; Polack A Oncogene; 1995 Apr; 10(7):1393-401. PubMed ID: 7731690 [TBL] [Abstract][Full Text] [Related]
11. MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. Leucci E; Cocco M; Onnis A; De Falco G; van Cleef P; Bellan C; van Rijk A; Nyagol J; Byakika B; Lazzi S; Tosi P; van Krieken H; Leoncini L J Pathol; 2008 Dec; 216(4):440-50. PubMed ID: 18802929 [TBL] [Abstract][Full Text] [Related]
12. Regulation of human telomerase activity: repression by normal chromosome 3 abolishes nuclear telomerase reverse transcriptase transcripts but does not affect c-Myc activity. Ducrest AL; Amacker M; Mathieu YD; Cuthbert AP; Trott DA; Newbold RF; Nabholz M; Lingner J Cancer Res; 2001 Oct; 61(20):7594-602. PubMed ID: 11606399 [TBL] [Abstract][Full Text] [Related]
13. Iron specific growth inhibition of Burkitt's lymphoma cells in vitro, associated with a decrease in translocated c-myc expression. Habel ME; Lemieux R; Jung D J Cell Physiol; 2005 Apr; 203(1):277-85. PubMed ID: 15468060 [TBL] [Abstract][Full Text] [Related]
14. Translocations among antibody genes in human cancer. Leder P IARC Sci Publ; 1985; (60):341-57. PubMed ID: 4065947 [TBL] [Abstract][Full Text] [Related]
15. Topological organization of the MYC/IGK locus in Burkitt's lymphoma cells assessed by nuclear halo preparations. Rätsch A; Joos S; Kioschis P; Lichter P Exp Cell Res; 2002 Feb; 273(1):12-20. PubMed ID: 11795942 [TBL] [Abstract][Full Text] [Related]
16. Level of MYC overexpression in pediatric Burkitt's lymphoma is strongly dependent on genomic breakpoint location within the MYC locus. Wilda M; Busch K; Klose I; Keller T; Woessmann W; Kreuder J; Harbott J; Borkhardt A Genes Chromosomes Cancer; 2004 Oct; 41(2):178-82. PubMed ID: 15287031 [TBL] [Abstract][Full Text] [Related]
17. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences. Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737 [TBL] [Abstract][Full Text] [Related]
18. Differential expression of the translocated and the untranslocated c-myc oncogene in Burkitt lymphoma. ar-Rushdi A; Nishikura K; Erikson J; Watt R; Rovera G; Croce CM Science; 1983 Oct; 222(4622):390-3. PubMed ID: 6414084 [TBL] [Abstract][Full Text] [Related]
19. Altered actin and immunoglobulin C mu expression in nitrogen mustard-resistant human Burkitt lymphoma cells. Tan KB; Grillone L; Boyce R; Crooke ST J Cell Biochem; 1989 Aug; 40(4):407-15. PubMed ID: 2506199 [TBL] [Abstract][Full Text] [Related]
20. Transcription enhancer identified near the human C mu immunoglobulin heavy chain gene is unavailable to the translocated c-myc gene in a Burkitt lymphoma. Rabbitts TH; Forster A; Baer R; Hamlyn PH Nature; 1983 Dec 22-1984 Jan 4; 306(5945):806-9. PubMed ID: 6419124 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]